                         SEQUENCE LISTING

<110>  Readygo Diagnostics Limited
 
<120>  Assay

<130>  PC931781WO

<150>  GB2108853.9
<151>  2021-06-21

<160>  17    

<170>  PatentIn version 3.5

<210>  1
<211>  9
<212>  DNA
<213>  SARS-CoV-2

<400>  1
atctgtcaa                                                                9


<210>  2
<211>  9
<212>  RNA
<213>  SARS-CoV-2

<400>  2
uugacagau                                                                9


<210>  3
<211>  20
<212>  DNA
<213>  Artificial Sequence

<220>
<223>  disDNA sequence

<400>  3
tcaagcagca gcaaagcaag                                                   20


<210>  4
<211>  9
<212>  DNA
<213>  Artificial Sequence

<220>
<223>  P2p primer

<400>  4
gtcaagcag                                                                9


<210>  5
<211>  9
<212>  DNA
<213>  Artificial Sequence

<220>
<223>  P2* primer

<400>  5
gttcaatct                                                                9


<210>  6
<211>  8
<212>  DNA
<213>  Artificial Sequence

<220>
<223>  P1c* primer

<400>  6
ctgattga                                                                 8


<210>  7
<211>  9
<212>  DNA
<213>  Artificial Sequence

<220>
<223>  P1 (csp) primer

<400>  7
agattgaac                                                                9


<210>  8
<211>  18
<212>  DNA
<213>  Artificial Sequence

<220>
<223>  Reporter oligo

<400>  8
ctgcttgaca gattgaac                                                     18


<210>  9
<211>  11
<212>  DNA
<213>  Artificial Sequence

<220>
<223>  Quencher oligo

<400>  9
ctgtcaagca g                                                            11


<210>  10
<211>  40
<212>  RNA
<213>  Artificial Sequence

<220>
<223>  RNA template

<400>  10
cuugcuuugc ugcugcuuga cagauugaac cagcuugaga                             40


<210>  11
<211>  18
<212>  DNA
<213>  Artificial Sequence

<220>
<223>  LIDA ligation product

<400>  11
gttcaatctg tcaagcag                                                     18


<210>  12
<211>  73
<212>  PRT
<213>  SARS-CoV-2

<400>  12

Met Leu Gln Ser Cys Tyr Asn Phe Leu Lys Glu Gln His Cys Gln Lys 
1               5                   10                  15      


Ala Ser Thr Gln Lys Gly Ala Glu Ala Ala Val Lys Pro Leu Leu Val 
            20                  25                  30          


Pro His His Val Val Ala Thr Val Gln Glu Ile Gln Leu Gln Ala Ala 
        35                  40                  45              


Val Gly Glu Leu Leu Leu Leu Glu Trp Leu Ala Met Ala Val Met Leu 
    50                  55                  60                  


Leu Leu Leu Cys Cys Cys Leu Thr Asp 
65                  70              


<210>  13
<211>  70
<212>  PRT
<213>  Human-CoV

<400>  13

Met Leu Pro Pro Cys Tyr Asn Phe Leu Lys Glu Gln His Cys Gln Lys 
1               5                   10                  15      


Ala Ser Thr Gln Arg Glu Ala Glu Ala Ala Val Lys Pro Leu Leu Ala 
            20                  25                  30          


Pro His His Val Val Ala Val Ile Gln Glu Ile Gln Leu Leu Ala Ala 
        35                  40                  45              


Val Gly Glu Ile Leu Leu Leu Ala Trp Leu Ala Glu Val Val Lys Leu 
    50                  55                  60                  


Pro Ser Arg Tyr Cys Cys 
65                  70  


<210>  14
<211>  70
<212>  PRT
<213>  Bat-CoV

<400>  14

Met Leu Pro Ser Cys Tyr Asn Phe Leu Lys Glu Gln His Cys Gln Lys 
1               5                   10                  15      


Ala Ser Thr Gln Arg Gly Ala Glu Val Ala Val Asn Leu His Leu Ala 
            20                  25                  30          


Pro His His Val Val Ala Val Ile Gln Glu Ile Gln Leu Leu Ala Ala 
        35                  40                  45              


Val Gly Glu Val Leu Leu Leu Asp Trp Leu Ala Glu Val Val Lys Leu 
    50                  55                  60                  


Pro Ser Arg Tyr Cys Cys 
65                  70  


<210>  15
<211>  170
<212>  DNA
<213>  SARS-CoV-2

<400>  15
tcgcaacagt tcaagaaatt caactccagg cagcagtagg ggaacttctc ctgctagaat       60

ggctggcaat ggcggtgatg ctgctcttgc tttgctgctg cttgacagat tgaaccagct      120

tgagagcaaa atgtctggta aaggccaaca acaacaaggc caaactgtca                 170


<210>  16
<211>  56
<212>  PRT
<213>  SARS-CoV-2

<400>  16

Val Ala Thr Val Gln Glu Ile Gln Leu Gln Ala Ala Val Gly Glu Leu 
1               5                   10                  15      


Leu Leu Leu Glu Trp Leu Ala Met Ala Val Met Leu Leu Leu Leu Cys 
            20                  25                  30          


Cys Cys Leu Thr Asp Thr Ser Leu Arg Ala Lys Cys Leu Val Lys Ala 
        35                  40                  45              


Asn Asn Asn Lys Ala Lys Leu Ser 
    50                  55      


<210>  17
<211>  170
<212>  DNA
<213>  SARS-CoV-2

<400>  17
agcgttgtca agttctttaa gttgaggtcc gtcgtcatcc ccttgaagag gacgatctta       60

ccgaccgtta ccgccactac gacgagaacg aaacgacgac gaactgtcta acttggtcga      120

actctcgttt tacagaccat ttccggttgt tgttgttccg gtttgacagt                 170


